Delving into the Latest Updates on MEDINET Co., Ltd. with Synapse

概览

疾病领域	数量

肿瘤	2

排名前五的药物类型	数量

树突状细胞疫苗	2
治疗性疫苗	2
合成肽疫苗	1

排名前五的靶点	数量

WT1(Wilms瘤基因l)	1

关联

2

项与 MEDINET Co., Ltd. 相关的药物

WT1 peptide-loaded dendritic cell product(MEDINET)

靶点

WT1

作用机制

WT1抑制剂 [+1]

在研机构

MEDINET Co., Ltd.

原研机构

MEDINET Co., Ltd.

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

HSP105 peptide-pulsed dendritic cell product(MEDINET)

靶点-

作用机制

细胞毒性T淋巴细胞刺激剂

在研机构

The University of Tokyo Hospital [+1]

原研机构

MEDINET Co., Ltd.

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

2

项与 MEDINET Co., Ltd. 相关的临床试验

JPRN-jRCTc030220374

/ Completed临床1期IIT

A study for the safety of NKT cell therapy using alpha-galactosylceramide-pulesed dendritic cells for malignant tumors - NKT cell therapy using alphaGC-DCs for malignant tumors

开始日期2022-10-14

申办/合作机构

MEDINET Co., Ltd.

JPRN-jRCTc030220287

/ Recruiting临床1期IIT

Study for Tolerability of abT-Cell Therapy in Patients Refractory to Immune Checkpoint Inhibitors - Tolerability of abT-Cell Therapy in Patients Refractory to ICIs

开始日期2022-09-15

申办/合作机构

MEDINET Co., Ltd.

100 项与 MEDINET Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 MEDINET Co., Ltd. 相关的专利（医药）

登录后查看更多信息

37

项与 MEDINET Co., Ltd. 相关的文献（医药）

2025-06-01·Regenerative Therapy

Regulatory insights on gene therapies, adeno-associated virus-based gene therapies, cell/tissue-based products, and medical care/practice in cell and gene therapies: Report from the 7th Asia partnership conference - April 25, 2024

Review

作者: Zhang, Alex J ; Kagawa, Yusuke ; Nomura, Masayuki ; Mizoguchi, Hirokuni ; Hayashi, Shigeaki ; Tsurumaki, Yoshie ; Miyano, Masaaki ; Suzuki, Kunihiko ; Shinozaki, Ruriko ; Fujii, Masaki ; Kellathur, Srinivasan N

The 7th Asia Partnership Conference of Regenerative Medicine (APACRM) was held both in person and online on April 25, 2024, to promote the regulatory harmonization of regenerative medicine products across Asia. Recognizing domestic regulatory guidelines and their underlying rationales within each country and region is an important initial step toward achieving harmonious regulation. The 7th APACRM featured open dialogues on the non-clinical evaluations of adeno-associated virus gene therapy products, regulation of gene therapies, considerations for conducting clinical trials, and provision of cell and gene therapies as medical practices without market authorization. These discussions included presentations by industry experts and panel discussions with regulatory agencies. The latest updates on regenerative medicine from each country and region were also introduced. This paper summarizes the proceedings of the 7th APACRM to foster future discussions and disseminate information to the public.

2024-06-01·Regenerative Therapy

Regulatory insights on advanced CAR-T cell products, AAV-based Gene therapies, and medical care/practice in cell and Gene therapies: Report from the 6th Asia partnership conference of regenerative medicine- April 20, 2023

Review

作者: Yoneda, Tomohiro ; Miyano, Masaaki ; Choi, Bryan ; Mizoguchi, Hirokuni ; Suzuki, Kunihiko ; Moriya, Yuu ; Takakura, Koji ; Muthusamy, Sasikumar ; Karasawa, Hiroshi ; Watanabe, Takeshi ; Hsieh, Chia-Ling ; Yuan, Ta-Tung ; Wen, Karen ; Tsurumaki, Yoshie ; Nomura, Masayuki

The 6th Asia Partnership Conference of Regenerative Medicine (APACRM) was held in person with online on April 20, 2023, to promote the regulatory harmonization of regenerative medicine products throughout Asia. Recognizing domestic regulatory guidelines within each country and region and the underlying rationales are important initial steps toward harmonizing regulations. The 6th APACRM featured an open dialog regarding non-clinical evaluation for advanced CAR-T products, regulation of clinical trials for AAV-based gene therapies, and cell and gene therapies provided to patients as medical care/medical practices without market authorization through presentations from the industry and panel discussions with regulatory agencies. The latest updates on regenerative medicine in each country and region are introduced. This paper summarizes the proceedings of the 6th APACRM for public dissemination to foster future discussions.

2018-03-04·OncoImmunology2区 · 医学

Dendritic cell vaccine induces antigen-specific CD8⁺ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade

2区 · 医学

ArticleOA

作者: Hosoi, Akihiro ; Matsushita, Hirokazu ; Iino, Tamaki ; Kakimi, Kazuhiro ; Morishita, Yasuyuki ; Nagaoka, Koji

The success of immune checkpoint blockade has unequivocally demonstrated that anti-tumor immunity plays a pivotal role in cancer therapy. Because endogenous tumor-specific T-cell responsiveness is essential for the success of checkpoint blockade, combination therapy with cancer vaccination may facilitate tumor rejection. To select the best vaccine strategy to combine with checkpoint blockade, we compared dendritic cell-based vaccines (DC-V) with peptide vaccines for induction of anti-tumor immunity that could overcome tumor-induced immunosuppression. Using B16 melanoma and B16-specific TCR-transgenic T-cells (pmel-1), we found that DC-V efficiently primed and expanded pmel-1 cells with an active effector and central memory phenotype that were not exhausted. Vaccine-primed cells were metabolically distinct from naïve cells. DC-V-primed pmel-1 cells contained the population that shifted metabolic pathways away from glycolysis to mitochondrial oxidative phosphorylation. They displayed better effector function and proliferated more than those induced by peptide vaccination. DC-V inhibited tumor growth in prophylactic and therapeutic settings. Only DC-V but not peptide vaccine showed augmented anti-tumor activity when combined with anti-PD-1 therapy. Thus, DC-V combined with PD-1 checkpoint blockade mediates optimal anti-cancer activity in this model.

100 项与 MEDINET Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 MEDINET Co., Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年05月18日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床2期

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

HSP105 peptide-pulsed dendritic cell product(MEDINET)	肿瘤更多	临床2期
WT1 peptide-loaded dendritic cell product(MEDINET) ( WT1 )	肿瘤更多	临床2期